Literature DB >> 344043

Plasma kallikrein activity and prekallikrein levels during endotoxin shock in dogs.

A O Aasen, W Frolich, O D Saugstad, E Amundsen.   

Abstract

Endotoxin shock (ES) was induced in Labrador retriever dogs by infusion of a lethal dose of Escherichia coli endotoxin. Spontaneous plasma kallikrein activity and prekallikrein levels were determined during subsequent stages of the shock both by an esterolytic assay (BAEe) and a new amidolytic assay utilizing a chromogenic tripeptide derivative (Chromozym PK, Prntapharm AG, Basel Switzerland). During the late stages of shock characterized by a substantial decline of blood pressure, plasma prekallikrein levels determined by the amidolytic assay were considerably reduced. In this phase of the shock both the esterolytic and the amidolytic assays revealed a significant elevation of spontaneous activity. Plasma prekallikrein determined by the esterolytic assay was found to be elevated vs. control values for the whole duration of ES. The findings made seem to associate activation of the plasma kallikrein-kinin system to the circulatory collapse of endotoxin shock in dogs.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 344043     DOI: 10.1159/000127992

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  3 in total

1.  Alpha 2 macroglobulin of the rat, an acute phase protein, mitigates the early course of endotoxin shock.

Authors:  H van Vugt; J van Gool; L de Ridder
Journal:  Br J Exp Pathol       Date:  1986-06

2.  Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor.

Authors:  R Guerrero; F Velasco; M Rodriguez; A Lopez; R Rojas; M A Alvarez; R Villalba; V Rubio; A Torres; D del Castillo
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

3.  Tissue Kallikrein Activity, Detected by a Novel Method, May Be a Predictor of Recurrent Stroke: A Case-Control Study.

Authors:  Xiao Ran; Qin Zhang; Dao Wen Wang
Journal:  Dis Markers       Date:  2015-09-14       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.